Oleogel S10

Drug Profile

Oleogel S10

Alternative Names: AP 101; Betulin-based oleogel; Episalvan; Oleogel-S10; Sericare

Latest Information Update: 01 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Birken GmbH
  • Developer Amryt Pharma
  • Class Herbal medicines; Skin disorder therapies; Triterpenes
  • Mechanism of Action Keratinocyte modulators; Transient receptor potential channel stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Registered Wounds
  • Phase III Burns; Epidermolysis bullosa
  • Phase II Actinic keratosis

Most Recent Events

  • 29 Mar 2017 Phase-III clinical trials in Epidermolysis bullosa (In adolescents, In children, In the elderly, In adults) in Spain (Topical) (EudraCT2016-002066-32)
  • 29 Mar 2017 Phase-III clinical trials in Epidermolysis bullosa (In children, In adolescents, In adults, In the elderly) in Australia (Topical) (NCT03068780)
  • 09 Dec 2016 Birken AG has been acquired by Amryt Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top